



HepQuant Names Clinical Accounts Manager, Lab Operations Manager

Herman, Cepeniene Accept Full-Time Roles at HepQuant

DENVER (May 15, 2017) -- HepQuant, LLC, a Greenwood Village, Colo.-based company with a unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease, today announced that Andrea Herman has come on board as Manager of Clinical Accounts (effective Feb. 13, 2017) and Dziuleta Cepeniene will serve as Laboratory Operations Manager (effective June 1, 2017).

“Both of these ‘new-hires’ have extensive experience and are quite familiar with HepQuant’s tests and business operations – they are not new to the HepQuant story at all,” noted HepQuant Founder and Chief Executive Officer Dr. Gregory T. Everson. “They both possess valuable experience with our technology, including the protocols involved in administering the tests and in measuring results. We are fortunate to gain their expertise on a full-time basis.”

Previously, Herman served as Project Manager at ClinicalRM, a contract research organization (CRO) based in Ohio that supports federal and commercial sponsors to develop vaccines, drugs, diagnostics, and medical devices. From 2005 to 2015, she was Senior Clinical Research Coordinator at the University of Colorado-Denver Anschutz Medical Campus where she coordinated multiple clinical studies focused on Hepatitis C and pre- and post-liver transplants, sponsored by pharmaceutical companies and National Institute of Health (NIH). In this position, she was actively involved in the development of the HepQuant liver function tests with Dr. Everson. Prior to UC-Denver, Herman served as Project Manager at ClinicalRM, a contract research organization (CRO).

In her role as Manager of Clinical Accounts and Quality Assurance, Herman is responsible for managing clinical sites and sponsors, providing project management and guidance to clinical sites. She provides essential quality assurance throughout the company and in support of HepQuant’s Regulatory Director.

As Laboratory Operations Manager, Cepeniene ensures the company’s laboratory operations meet regulatory requirements and business objectives. She is in charge of processing HepQuant SHUNT Testing patient blood samples for LCMS and analyzing the data to generate the testing



results. She reports these results to HepQuant clients, including pharmaceutical companies and independent principal investigators at various academic institutions. She possesses specialized experience in peptide purification and analysis using reversed phase LC, HPLC (high performance liquid chromatography) and Mass Spectrometry.

About HepQuant

HepQuant products are investigational combination drug / diagnostic devices and have not yet been evaluated or approved by the US Food and Drug Administration (FDA) for commercial sale. They are currently available for investigational use via the FDA IDE application process. For additional information, please visit our website at www.hepquant.com.

MEDIA CONTACT

Tom Kennedy, Corporate Communications

Ph: (303) 548-3056 | E: tom.kennedy@hepquant.com